Regeneron’s Pasatru Enters Ultra-Rare Bone Market

Regeneron Pharmaceuticals (REGN.O) surged 4% Wednesday after the FDA approved Pasatru for a bone-hardening disorder, adding a second approved rival to Ipsen’s Sohonos in a market affecting fewer than 1,000 diagnosed patients globally.1 The approval hands Regeneron a commercial foothold in an ultra-orphan segment where pricing power is typically high, and it arrives as biotech […]